Xianxing J. Jiang

132 East Outer Ring Road
Guangzhou, 510006, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 55 publications

Structure-Based Development of a Novel Macrocyclic Peptide to Disrupt the Lumican-Collagen I Interaction in Liver Fibrosis.

Structure-Based Development of a Novel Macrocyclic Peptide to Disrupt the Lumican-Collagen I Interaction in Liver Fibrosis.

Journal: Journal of medicinal chemistry

Published: November 28, 2025

A novel GCGR/GLP-1R dual-agonist TB001 ameliorates kidney fibrosis via inhibiting PERK-mediated endoplasmic reticulum stress pathway.

A novel GCGR/GLP-1R dual-agonist TB001 ameliorates kidney fibrosis via inhibiting PERK-mediated endoplasmic reticulum stress pathway.

Journal: Frontiers in immunology

Published: July 14, 2025

Discovery of Novel Cyclic Peptides as SMAD2-SMAD4 Interaction Inhibitors for the Treatment of Hepatic Fibrosis.

Discovery of Novel Cyclic Peptides as SMAD2-SMAD4 Interaction Inhibitors for the Treatment of Hepatic Fibrosis.

Journal: Journal of medicinal chemistry

Published: May 05, 2025

MYD88 regulates the intercellular crosstalk landscape in MASH liver against metaflammation and metabolic disorder.

MYD88 regulates the intercellular crosstalk landscape in MASH liver against metaflammation and metabolic disorder.

Journal: Acta pharmaceutica Sinica. B

Published: March 06, 2025

Discovery of Novel Peptide Antagonists Targeting GPR55 for Liver Inflammation and Fibrosis.

Discovery of Novel Peptide Antagonists Targeting GPR55 for Liver Inflammation and Fibrosis.

Journal: Journal of medicinal chemistry

Published: July 11, 2024

The novel peptide PEP-Z-2 potentially treats renal fibrosis in vivo and in vitro by regulating TGF-β/Smad/AKT/MAPK signaling.

The novel peptide PEP-Z-2 potentially treats renal fibrosis in vivo and in vitro by regulating TGF-β/Smad/AKT/MAPK signaling.

Journal: European journal of pharmacology

Published: May 21, 2024

Dual activation of GCGR/GLP1R signaling ameliorates intestinal fibrosis via metabolic regulation of histone H3K9 lactylation in epithelial cells.

Dual activation of GCGR/GLP1R signaling ameliorates intestinal fibrosis via metabolic regulation of histone H3K9 lactylation in epithelial cells.

Journal: Acta pharmaceutica Sinica. B

Published: April 11, 2024

Design and Synthesis of Novel Ultralong-Acting Peptides as EDP-EBP Interaction Inhibitors for Pulmonary Fibrosis Treatment.

Design and Synthesis of Novel Ultralong-Acting Peptides as EDP-EBP Interaction Inhibitors for Pulmonary Fibrosis Treatment.

Journal: Journal of medicinal chemistry

Published: April 08, 2024

The roles and potential mechanisms of plant polysaccharides in liver diseases: a review.

The roles and potential mechanisms of plant polysaccharides in liver diseases: a review.

Journal: Frontiers in pharmacology

Published: March 14, 2024

Design and discovery of a highly potent ultralong-acting GLP-1 and glucagon co-agonist for attenuating renal fibrosis.

Design and discovery of a highly potent ultralong-acting GLP-1 and glucagon co-agonist for attenuating renal fibrosis.

Journal: Acta pharmaceutica Sinica. B

Published: July 19, 2023

Discovery and Design of Novel Cyclic Peptides as Specific Inhibitors Targeting CCN2 and Disrupting CCN2/EGFR Interaction for Kidney Fibrosis Treatment.

Discovery and Design of Novel Cyclic Peptides as Specific Inhibitors Targeting CCN2 and Disrupting CCN2/EGFR Interaction for Kidney Fibrosis Treatment.

Journal: Journal of medicinal chemistry

Published: June 06, 2023

Design and Discovery of Novel Cyclic Peptides as EDPs-EBP Interaction Inhibitors for the Treatment of Liver Fibrosis.

Design and Discovery of Novel Cyclic Peptides as EDPs-EBP Interaction Inhibitors for the Treatment of Liver Fibrosis.

Journal: Journal of medicinal chemistry

Published: March 20, 2023

Showing 1-12 of 55

Last Updated: 09/26/2026